Details Basic Details Approval Date Monday, October 29, 2018 Original Posting Date Monday, October 17, 2022 Health Outcome(s) renal cell carcinoma Regulatory Link(s) (1) FDA Supplement Approval and ARIA Memo Link(s) Sentinel Drug Study: Invokana (Canagliflozin) & Renal Cell Carcinoma